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Adjusting for age above 50 years old, gender and breast
cancer, the mean hemoglobin value prior to anemia 
diagnosis was 11.2g/dL (95% CI; 11.0, 11.3). CON-
CLUSION: These data suggest that many patients who
become anemic during chemotherapy (≥Grade 1 anemia)
do not receive an anemia diagnosis. At hemoglobin values
below 10g/dL, the level at which the National Compre-
hensive Cancer Network (NCCN) most strongly recom-
mends consideration of aggressive anemia treatment, only
two-thirds of patients were identiﬁed as anemic by an
ICD-9 code. Our ﬁndings provide evidence that identify-
ing patients with ICD-9 codes for anemia from claims
data may be misleading and can signiﬁcantly underesti-
mate the true number of patients with anemia.
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OBJECTIVE: Chemotherapy-induced anemia is a
concern in oncology patients. The objective of this study
was to assess patterns of treatment with erythropoietic
therapy among oncology patients in a managed care
setting, and compare with the National Comprehensive
Cancer Network (NCCN) cancer and treatment-related
anemia clinical practice guideline recommendations.
METHODS: Members of a health plan who received
chemotherapy and erythropoietin and had access to lab-
oratory result data between January 1, 2002 and Febru-
ary 28, 2002 were included. Data were analyzed to
examine factors that were signiﬁcantly associated with
use of erythropoietic therapy stratiﬁed by nadir hemo-
globin categories. RESULTS: A total of 2560 patients
were identiﬁed. Erythropoietic therapy was initiated in
615 (45%) patients whose hemoglobin dropped below 12
g/dL, 443 (52%) patients whose hemoglobin dropped
below 11g/dL (NCCN hemoglobin level to consider ery-
thropoietic therapy), and 275 (62.5%) patients whose
hemoglobin dropped below 10g/dL (NCCN hemoglobin
level to strongly consider erythropoietic therapy). Multi-
variate analysis revealed that the mean probability of
receiving erythropoietic therapy was 0.34 (95% CI;
0.27–0.42) for patients whose hemoglobin fell between
10.5g/dL and 10.9g/dL; 0.44 (0.36–0.53) for patients
who reached a low between 10.0g/dL and 10.4g/dL; and
0.67 (0.61–0.72) for patients who dropped below 10.0
g/dL controlling for cancer type, blood administration, ﬁl-
grastim and select chemotherapeutic usage, hypertension
and diagnosis of anemia. Patients who received erythro-
poietic therapy were initiated following a mean adjusted
hemoglobin of 10.4g/dL (10.3g/dL–10.6g/dL). CON-
CLUSIONS: These data suggest a treatment gap in
patients whose hemoglobin levels drop below thresholds
set by the NCCN guidelines.
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Haemophilia treatment is very expensive and therapy has
to be life-long. In comparison with other diseases—e.g.,
diabetes—haemophilia is rare occurring in approximately
1 :10,000. OBJECTIVE: To determine the incremental
cost-effectiveness of prophylactic treatment compared
with on-demand treatment in patients with haemophilia
over a 1-year period from the third-party payers’ per-
spective. METHODS: A decision-tree model was devel-
oped to compare clinical outcomes, quality-adjusted life
years, and costs of prophylactic vs. on-demand treatment
for three European countries: Germany, Sweden, and the
United Kingdom. The time horizon of the decision-
analytic model was one year. Health effects were pre-
sented in terms of quality-adjusted life years gained
(QALYs) and in avoided bleeds as clinical outcome.
RESULTS: A total of 506 patients were included. Incre-
mental cost-effectiveness ratio (ICER) for prophylactic
treatment in one year for HIV-infected patients younger
than 30 years ranged from €1.24 million/QALY
(Germany) to €1.73 million/QALY (United Kingdom).
For Sweden, the ICER could not be calculated, because
all patients younger than 30 received prophylactic treat-
ment. For HIV-negative patients younger than 30 years,
ICER ranged from €2.21 million/QALY (Germany) to
€3.10 million/QALY (UK). These values were higher than
in the HIV-infected group, because the incremental effec-
tiveness of prophylactic treatment was smaller in HIV-
negative patients. In patients older than 30 years, ICERs
were even higher in HIV-negative patients, ranging from
€4.77 million/QALY (Germany) to €5.7 million/QALY
(Sweden and UK). In HIV-infected persons older than 30,
on-demand treatment dominates prophylactic treatment.
Prophylactic treatment was more expensive but yielded
slightly lower QALY values. CONCLUSION: Based on
our analysis and within the limitations of our short-term
model, prophylactic treatment has an extremely high
cost-effectiveness ratio when only a 1-year time horizon
is considered. Further research should focus on the long-
term consequences of the examined strategies.
